Metabolism News and Research

Latest Metabolism News and Research

Weight loss surgery and exercise lower risks of serious health problems

Throughout the past year, studies on the positive effects of weight loss surgery have been published in a variety of medical journals in the US and abroad. We learned that weight loss surgery is relatively safe, and that it is effective in improving serious health conditions. More recently, we also learned that it is a factor in preventing Type 2 diabetes from developing in people considered to be pre-diabetic.

9 Dec 2014

McMaster University researchers identify hormone that contributes to obesity, diabetes

Researchers from McMaster University have identified an important hormone that is elevated in obese people and contributes to obesity and diabetes by inhibiting brown fat activity.

8 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

Physical activity increases oxidative stress, and therefore, as an antioxidant vitamin C might have particularly evident effects on people who are participating in vigorous exercise. In several studies, vitamin C administration attenuated the increases in oxidative stress markers caused by exercise. Furthermore, vitamin C is involved in the metabolism of histamine, prostaglandins, and cysteinyl leukotrienes, all of which appear to be mediators in the pathogenesis of exercise-induced bronchoconstriction.

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Weight-loss surgery may reduce lower urinary tract symptoms

Metabolic syndrome is linked with an increased frequency and severity of lower urinary tract symptoms, but weight loss surgery may lessen these symptoms. The findings, which come from two studies published in BJU International, indicate that urinary problems may be added to the list of issues that can improve with efforts that address altered metabolism.

8 Dec 2014

New type of cancer therapy shows promise in patients with advanced leukemia

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology.

8 Dec 2014

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.

6 Dec 2014

Researchers suggest new strategy to control cellular identity and fate

A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.

6 Dec 2014

Researchers discover essential role of intestinal immune system in controlling energy metabolism

A group of UCL researchers (Louvain Drug Research Institute) identified an unsuspected mechanism impacting the development of obesity and diabetes type 2 after following a diet with a high dose of fat nutrition.

5 Dec 2014

Growth genes seem different in Hunger Winter children

Individuals conceived in the severe Dutch Famine, also called the Hunger Winter, may have adjusted to this horrendous period of World War II by making adaptations to how active their DNA is. Genes involved in growth and development were differentially regulated, according to researchers at the Leiden University Medical Center, Harvard University, and Columbia University's Mailman School of Public Health.

5 Dec 2014

Endocrine disrupting chemicals can alter thyroid levels in pregnant women, may affect fetus

A new study led by biologist R. Thomas Zoeller of the University of Massachusetts Amherst provides "the strongest evidence to date" that endocrine disrupting chemicals such as polychlorinated biphenyls (PCB) found in flame retardant cloth, paint, adhesives and electrical transformers, can interfere with thyroid hormone action in pregnant women and may travel across the placenta to affect the fetus.

5 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

Blue light can knock circadian rhythms off-kilter, study finds

A study funded by the National Institutes of Health is unraveling the mystery of how blue light from residential and commercial lighting, electronic devices, outdoor lights and billboards can throw off-kilter the natural body clock of humans, plants and animals, leading to disease.

3 Dec 2014

Study finds that cancer cells may be susceptible to metabolic stress

Research at the University of Adelaide has discovered cancer cells may be particularly susceptible to metabolic stress - opening the way for new targeted therapy that won't harm normal cells.

3 Dec 2014

Elevated anxious temperament associated with neuropeptide Y receptors

Persistent anxiety is one of the most common and distressing symptoms compromising mental health. Most of the research on the neurobiology of anxiety has focused on the generation of increased anxiety, i.e., the processes that "turn on" anxiety.

3 Dec 2014

Researchers find way to prevent noise-induced hearing loss

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein.

3 Dec 2014

New FDA data shows disparities still exist in medical research

The U.S. Food and Drug Administration (FDA) released data today on a dedicated website from six studies reflecting a two-month period in response to a requirement under the "FDA Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data" to make transparent the percentage of female and minority participation in clinical trials for medications intended for all populations.

2 Dec 2014

Pain medicine specialist receives award for new advances in oral fluid testing

This year's Eastern Pain Society Scientific meeting was held at Mount Sinai Beth Israel Medical Center in New York City in late October and is one of the largest meetings of pain physicians and fellows in the tri-state area.

2 Dec 2014

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye.

1 Dec 2014

Metabolism News and Research

Latest Metabolism News and Research

Weight loss surgery and exercise lower risks of serious health problems

McMaster University researchers identify hormone that contributes to obesity, diabetes

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Weight-loss surgery may reduce lower urinary tract symptoms

New type of cancer therapy shows promise in patients with advanced leukemia

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Researchers suggest new strategy to control cellular identity and fate

Researchers discover essential role of intestinal immune system in controlling energy metabolism

Growth genes seem different in Hunger Winter children

Endocrine disrupting chemicals can alter thyroid levels in pregnant women, may affect fetus

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Blue light can knock circadian rhythms off-kilter, study finds

Study finds that cancer cells may be susceptible to metabolic stress

Elevated anxious temperament associated with neuropeptide Y receptors

Researchers find way to prevent noise-induced hearing loss

New FDA data shows disparities still exist in medical research

Pain medicine specialist receives award for new advances in oral fluid testing

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy